Next Article in Journal
NSAIDs and Acute Pancreatitis: A Systematic Review
Next Article in Special Issue
Differential Proteomics Identification of HSP90 as Potential Serum Biomarker in Hepatocellular Carcinoma by Two-dimensional Electrophoresis and Mass Spectrometry
Previous Article in Journal
Inhaled Corticosteroids
Previous Article in Special Issue
Real Time Imaging of Biomarkers in the Parkinson's Brain Using Mini-Implantable Biosensors. II. Pharmaceutical Therapy with Bromocriptine
Pharmaceuticals 2010, 3(3), 541-557; doi:10.3390/ph3030541

Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure

 and *
Department of Chemistry & Biochemistry, University of Delaware, Newark, DE, 19716, USA
* Author to whom correspondence should be addressed.
Received: 9 January 2010 / Revised: 7 February 2010 / Accepted: 5 March 2010 / Published: 8 March 2010
(This article belongs to the Special Issue Biomarkers)
View Full-Text   |   Download PDF [2256 KB, uploaded 8 March 2010]   |   Browse Figures


Plasma platelet-activating factor acetylhydrolase (PAF-AH), also called lipoprotein-associated phospholipase A2 (Lp-PLA2), is a group VIIA PLA2 enzyme that catalyzes the hydrolysis of PAF and certain oxidized phospholipids. Although the role of PAF-AH as a pro- or anti-atherosclerotic enzyme is highly debated, several studies have shown it to be an independent marker of cardiovascular diseases. In humans the majority of plasma PAF-AH is bound to LDL and a smaller portion to HDL; the majority of the enzyme being associated with small dense LDL and VHDL-1 subclasses. Several studies suggest that the anti- or pro-atherosclerotic tendency of PAF-AH might be dependent on the type of lipoprotein it is associated with. Amino acid residues in PAF-AH necessary for binding to LDL and HDL have been identified. However our understanding of the interaction of PAF-AH with LDL and HDL is still incomplete. In this review we present an overview of what is already known about the interaction of PAF-AH with lipoprotein particles, and we pose questions that are yet to be answered. The recently solved crystal structure of PAF-AH, along with functional work done by others is used as a guide to develop a model of interaction of PAF-AH with lipoprotein particles.
Keywords: PAF-AH; Lp-PLA2; group VIIA PLA2; lipoprotein; i-face PAF-AH; Lp-PLA2; group VIIA PLA2; lipoprotein; i-face
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Srinivasan, P.; Bahnson, B.J. Molecular Model of Plasma PAF Acetylhydrolase-Lipoprotein Association: Insights from the Structure. Pharmaceuticals 2010, 3, 541-557.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert